Search research articles
Contact Us
Filters
Showing results (271-280 of 418) with videos related to
Page
of 42
Sort By:
Pigment Cell & Melanoma Research
|
August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeutics
Jason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
The Lancet. Oncology
|
March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Jiayi Yu, Junya Yan, Qian Guo, et al.
The Lancet. Oncology
|
September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
The Lancet. Oncology
|
February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrity
Paul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
JCO Precision Oncology
|
February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
Neal Akhave, Zihe Song, David S Hong, et al.
Cell Reports
|
April 22, 2014
Isolation and molecular characterization of circulating melanoma cells
Xi Luo, Devarati Mitra, Ryan J Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Page
of 42
Search research articles
Search
Showing results (271-280 of 418) with videos related to
Sort By:
Page
of 42
Pigment Cell & Melanoma Research
|
August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeutics
Jason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
The Lancet. Oncology
|
March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Jiayi Yu, Junya Yan, Qian Guo, et al.
The Lancet. Oncology
|
September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
The Lancet. Oncology
|
February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrity
Paul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
JCO Precision Oncology
|
February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
Neal Akhave, Zihe Song, David S Hong, et al.
Cell Reports
|
April 22, 2014
Isolation and molecular characterization of circulating melanoma cells
Xi Luo, Devarati Mitra, Ryan J Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Page
of 42